Abstract:The DrugMatrix Database contains systematically generated toxicogenomics data from short-term in vivo studies for over 600 chemicals. However, most of the potential endpoints in the database are missing due to a lack of experimental measurements. We present our study on leveraging matrix factorization and machine learning methods to predict the missing values in the DrugMatrix, which includes gene expression across eight tissues on two expression platforms along with paired clinical chemistry, hematology, and histopathology measurements. One major challenge we encounter is the skewed distribution of the available measured data, in terms of both tissue sources and values. We propose a method, ToxiCompl, that applies systematic hybrid sampling guided by Bayesian optimization in conjunction with low-rank matrix factorization to recover the missing values. ToxiCompl achieves good training and validation performance from a machine learning perspective. We further conduct an in-depth validation of the predicted data from biological and toxicological perspectives with a series of analyses. These include examining the connectivity pattern of predicted gene expression responses, characterizing molecular pathway-level responses from sets of differentially expressed genes, evaluating known transcriptional biomarkers of tissue toxicity, and characterizing pre-dicted apical endpoints. Our analysis shows that the predicted differential gene expression, broadly speaking, aligns with what would be anticipated. For example, in most instances, our predicted differentially expressed gene lists offer a connectivity level comparable to that of measured data in connectivity analysis. Using Havcr1, a known transcriptional biomarker of kidney injury, we identify treatments that, based on the predicted expression data, manifest kidney toxicity in a manner that is mechanistically plausible and supported by the literature. Characterization of the predicted clinical chemistry data suggests that strong effects are relatively reliably predicted, while more subtle effects pose a greater challenge. In the case of histopathological prediction, we find a significant overprediction due to positivity bias in the measured data. Developing methods to deal with this bias is one of the areas we plan to target for future improvement. The main advantage of the ToxiCompl approach is that, in the absence of additional experimental data, it drastically extends the toxicogenomic landscape into a number of data-poor tissues, thereby allowing researchers to formulate mechanistic hypotheses about effects in tissues that have been underrepresented in the literature. All measured and predicted DrugMatrix data (i.e., gene expression, clinical chemistry, hematology, and histopathology) are available to the public through an intuitive GUI interface that allows for data retrieval, gene set analysis and high dimensional visualization of gene expression similarity ( ).

Bayesian Matrix Completion for Hypothesis Testing

A permutation-based approach to inference for weighted sum regression with correlated chemical mixtures

Bayesian joint modeling of chemical structure and dose response curves

Bayesian kernel machine regression for estimating the health effects of multi-pollutant mixtures

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Optimal Bayesian Hierarchical Model to Accelerate the Development of Tissue-Agnostic Drugs and Basket Trials.

Bayesian Nonparametric Risk Assessment in Developmental Toxicity Studies with Ordinal Responses

Gene Target Prediction of Environmental Chemicals Using Coupled Matrix-Matrix Completion

DIVERSE: Bayesian Data IntegratiVE learning for precise drug ResponSE prediction

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Bayesian Multi Plate High Throughput Screening of Compounds

Estimating the health effects of environmental mixtures using Bayesian semiparametric regression and sparsity inducing priors

Bayesian semi-supervised learning for uncertainty-calibrated prediction of molecular properties and active learning

Reflected generalized concentration addition and Bayesian hierarchical models to improve chemical mixture prediction

Bayesian outcome selection modelling

Combining human cell line transcriptome analysis and Bayesian inference to build trustworthy machine learning models for prediction of animal toxicity in drug development

Completion of the DrugMatrix Toxicogenomics Database using ToxCompl

Bayesian Benchmark Dose Analysis

Bayesian inference for identifying tumour-specific cancer dependencies through integration of ex-vivo drug response assays and drug-protein profiling

Bayesian Multivariate Probability of Success Using Historical Data with Strict Control of Family-wise Error Rate

Embracing assay heterogeneity with neural processes for markedly improved bioactivity predictions